Mydecine Innovations Group
Mydecine (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is a vertically integrated life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. Mydecine focuses on three areas:
- Global Clinical Trials
- R&D-Robust IP Portfolio
- Technology-Advanced HIPAA Compliant telehealth platform
CEO & Co-Founder
Mydecine Innovations Group
David Joshua Bartch is Director, President & CEO of Mydecine Innovations Group. Mr. Bartch’s entrepreneurial career took off in 2009 when he co-founded AudioTranscriptionist.com and founded the Denver based dispensary, Doctors Orders. Following these ventures, Mr. Bartch founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA’s most significant legal and sophisticated cannabis wholesale platform. In 2015, Cannabase.io was acquired by Helix TCS.
Contact Us
Website:
https://www.mydecine.com/#investors
Email:
hello@mydecineinc.com
Phone Number:
720-277-9879